Immutep doses First Patient in TACTI-002 Phase II Trial
March 06, 2019 08:00 ET
|
Immutep Limited
The First Patient has been dosed at “START Madrid- FJD” in SpainClinical trial sites are active and more will be activated and commence recruitment in coming months SYDNEY, Australia, March 06, 2019...
Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma
March 06, 2019 08:00 ET
|
Immutep Limited
Presented at the World Immunotherapy Congress USA 2019 SYDNEY, Australia, March 06, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology...
Immutep to Present at Oppenheimer’s 29th Annual Healthcare Conference
March 04, 2019 08:00 ET
|
Immutep Limited
SYDNEY, Australia, March 04, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer...
Immutep to Present at Upcoming Industry Conferences
February 26, 2019 08:00 ET
|
Immutep Limited
SYDNEY, Australia, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer...
Immutep Enters Into Clinical Trial Collaboration, Service and Supply Agreement With CYTLIMIC
January 07, 2019 08:00 ET
|
Immutep Limited
New clinical trial collaboration with CYTLIMIC to test eftilagimod alpha (“efti” or “IMP321”) as part of a cancer peptide vaccine discovered by artificial intelligenceBuilds on Immutep’s longstanding...
Immutep Announces US$5.2 Million Financing Led by U.S. Specialist Healthcare Investor, Altium Capital
December 19, 2018 07:00 ET
|
Immutep Limited
Extends the Company’s cash runway into mid-2020, during which time Immutep is expected to report meaningful clinical data SYDNEY, Australia, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:...
New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented at the 4th Annual ICI Europe Summit
November 27, 2018 08:00 ET
|
Immutep Limited
SYDNEY, Australia, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), announces new data from its ongoing TACTI-mel Phase I clinical trial is...
Immutep Presents Positive New Data from Ongoing TACTI-mel Study at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
November 12, 2018 08:00 ET
|
Immutep Limited
SYDNEY, Australia, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...
Operational Update
November 01, 2018 08:00 ET
|
Immutep Limited
Highlights Site selection process advancing for planned TACTI-002 Phase II trial which will include recruitment of up to 110 patientsAIPAC Phase IIb recruitment reaches 155 patients or more than 68%...
Immutep Announces Data Presentations at Upcoming Industry Conferences
October 24, 2018 08:00 ET
|
Immutep Limited
SYDNEY, Australia, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...